Rubius Therapeutics, Inc. (RUBY)
Stock Price:
$6.25 USD
0.10 (1.63%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
502.98M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-179.36M |
| Shares Out |
80.48M |
| EPS (ttm) |
-2.26 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$6.25 |
| Previous Close |
$6.15 |
| Change ($) |
0.10 |
| Change (%) |
1.63% |
| Day's Open |
6.27 |
| Day's Range |
6.05 - 6.30 |
| Day's Volume |
200,890 |
| 52-Week Range |
3.35 - 16.16 |
More Stats
| Market Cap |
502.98M |
| Enterprise Value |
354.73M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
80.48M |
| Float |
35.71M |
| EPS (basic) |
-2.25 |
| EPS (diluted) |
-2.26 |
| FCF / Share |
-2.08 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.09M |
| Short Ratio |
33.26 |
| Short % of Float |
26.88% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.27 |
| Revenue |
n/a |
| Operating Income |
-184.05M |
| Net Income |
-179.36M |
| Free Cash Flow |
-166.93M |
| Net Cash |
148.24M |
| Net Cash / Share |
1.84 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-29.13% |
| ROE |
-59.12% |
| ROIC |
-51.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
3 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
1 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$10.00*
(60.00% upside)
Low
3.00
Current: 6.25
High
28.00
Target: 10.00
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -170 | -91.66 | -43.26 | -10.85 |
| Net Income | -163 | -89.20 | -43.85 | -11.02 |
| Shares Outstanding | 78.69 | 39.29 | 8.02 | 7.20 |
| Earnings Per Share | -2.08 | -2.27 | -5.55 | -1.63 |
| Operating Cash Flow | -110 | -58.34 | -21.94 | -9.50 |
| Capital Expenditures | -40.66 | -14.95 | -2.25 | -0.44 |
| Free Cash Flow | -151 | -73.29 | -24.19 | -9.95 |
| Cash & Equivalents | 285 | 406 | 105 | 7.07 |
| Total Debt | 97.00 | 65.79 | 5.44 | 3.92 |
| Net Cash / Debt | 188 | 341 | 99.13 | 3.14 |
| Assets | 395 | 479 | 108 | 7.99 |
| Liabilities | 121 | 86.10 | 11.58 | 6.05 |
| Book Value | 274 | 393 | -43.69 | -17.12 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Rubius Therapeutics, Inc. |
| Country |
United States |
| Employees |
195 |
| CEO |
Pablo J. Cagnoni |
Stock Information
| Ticker Symbol |
RUBY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RUBY |
| IPO Date |
July 18, 2018 |
Description
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.